# A Novel Primary Cell Line Model of Localized Prostate Cancer and Radioresistance—A Role for Nicotinamide N-Methyltransferase

**Authors:** Jessica A. Wright, Stephanie D. White, Gavin Frame, Ana Bosiljkov, Shahbaz Khan, Roni Haas, Qian Yang, Minzhi Sheng, Xiaoyong Huang, Geoff S. Higgins, Ian Mills, Michelle R. Downes, Danny Vesprini, Hans T. Chung, Robert A. Screaton, Hon S. Leong, Paul C. Boutros, Thomas Kislinger, Stanley K. Liu

PMC · DOI: 10.3390/cells14110819 · 2025-05-31

## TL;DR

Researchers developed a new prostate cancer cell line and a radioresistant version to study treatment resistance and identified a gene, NNMT, that could help make radiotherapy more effective.

## Contribution

A novel primary prostate cancer cell line and a paired radioresistant subline were developed, with NNMT identified as a radiosensitization target.

## Key findings

- NNMT was the most dysregulated gene in the radioresistant CaB34-CF cell line.
- Knockdown of NNMT increased radiosensitivity through cellular senescence in CaB34-CF cells.
- 3D organoid assays confirmed radiosensitization effects of NNMT knockdown.

## Abstract

Prostate cancer cell lines are particularly clinically homogenous, mostly representing metastatic states rather than localized disease. While there has been significant work in the development of additional models, few have been created without oncogenic transformation. We derived a primary prostate cancer cell line from a patient with localized Gleason 7 prostate cancer—designated CaB34—which spontaneously immortalized. We leveraged CaB34 to generate a paired radioresistant subline, CaB34-CF, using a clinically relevant fractionated radiotherapy schedule. These two paired cell lines were investigated extensively to determine their molecular characteristics and therapy responses. Both CaB34 and CaB34-CF express prostate-specific markers, including KRT18, NKX3.1, and AMACR. Multi-omic analyses using RNAseq and shotgun proteomics identified NNMT as the most significantly dysregulated component in CaB34-CF. A bioinformatic analysis determined that NNMT was more abundant within prostate tumors compared to benign prostate, suggesting a role in tumor progression. Knockdown studies of NNMT demonstrated significant radiosensitization of CaB34-CF cells, which was largely a result of increased radiation-induced cellular senescence. Growth as 3D organoids was significantly higher in the CaB34-CF line, and demonstrated a less structured pattern of expression of cytokeratin markers. Radiosensitization with NNMT siRNA was recapitulated in a 3D organoid clonogenic assay in CaB34-CF cells. Our research provides a paired primary model of treatment-naïve and radioresistant disease to address mechanisms of therapy resistance, while expanding the repertoire of localized prostate cancer cell lines for the research community. In addition, our findings present NNMT as a potential therapeutic target for sensitization of radioresistant disease.

## Linked entities

- **Genes:** NNMT (nicotinamide N-methyltransferase) [NCBI Gene 4837], KRT18 (keratin 18) [NCBI Gene 3875], NKX3-1 (NK3 homeobox 1) [NCBI Gene 4824], AMACR (alpha-methylacyl-CoA racemase) [NCBI Gene 23600]
- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Genes:** KRT18 (keratin 18) [NCBI Gene 3875] {aka CK-18, CYK18, K18}, NNMT (nicotinamide N-methyltransferase) [NCBI Gene 4837], AMACR (alpha-methylacyl-CoA racemase) [NCBI Gene 23600] {aka AMACRD, CBAS4, P504S, RACE, RM}, NKX3-1 (NK3 homeobox 1) [NCBI Gene 4824] {aka BAPX2, NKX3, NKX3.1, NKX3A}
- **Diseases:** Gleason 7 (MESH:C537955), tumor (MESH:D009369), prostate tumors (MESH:D011472), Prostate Cancer (MESH:D011471)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** CaB34-CF — Choristoneura fumiferana (Spruce budworm moth), Spontaneously immortalized cell line (CVCL_WV91), CaB34 — Mus musculus (Mouse), Hybridoma (CVCL_J663)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12153919/full.md

---
Source: https://tomesphere.com/paper/PMC12153919